Therapeutic Apheresis · Review 02
Plasma exchange and longevity: promising biomarkers are not longer life
Animal findings and early human biomarker trials justify research, but they do not yet demonstrate longer life, better healthspan or durable clinical benefit.
- PROCEDURE STATUS
- Established medical procedure
- INDICATION EVIDENCE
- Early human biomarker evidence; no longevity outcome evidence
- REVIEW STATUS
- Clinical review required
- NEXT REVIEW
- January 2027
In short
Plasma exchange has produced interesting aging-related changes in mice and in small human biomarker studies. Human results are not consistent, and no trial has shown that it extends lifespan, prevents age-related disease or improves long-term healthspan. The evidence supports further study, not a proven longevity claim.
The clinical question
Does plasma exchange improve human longevity or healthspan, rather than only changing aging-related biomarkers?
Where the longevity hypothesis comes from
Mouse experiments found that replacing part of old plasma with saline and albumin changed circulating proteins and improved selected tissue-repair, liver and neurogenesis measures. These experiments support a dilution hypothesis: reducing age-associated circulating factors may reset parts of the signaling environment without adding young plasma.[1][2]
These are mechanistic and preclinical findings. An old mouse showing a laboratory or tissue change is not evidence that a person will live longer, avoid disease or function better over time.[1][2]
What early human studies found
A 2022 exploratory study reported shifts in a ten-protein biological-age measure after repeated plasma exchange. A 2025 randomized study of 42 adults reported improvement across several molecular aging clocks, particularly in a plasma-exchange-plus-IVIG group.[3][4]
These results are signals in surrogate measures. The 2025 study was small, tested several regimens and reported commercial involvement among authors. It did not establish effects on disease, disability, cognition, cardiovascular events or survival.[4]
The human evidence is already conflicting
A separate 2025 cross-over trial in healthy adults found no significant epigenetic rejuvenation. Several clocks moved in an unfavorable direction, and the authors concluded that the tested protocol did not provide conclusive evidence of benefit and required further long-term safety research.[5]
Marker change is not outcome
Even a favorable epigenetic or proteomic clock does not demonstrate that a person will live longer, remain independent longer or develop fewer age-related diseases.
What remains unknown
There is no settled protocol for a longevity indication, no validated responder profile, no demonstrated durability of benefit and no trial with lifespan or major healthspan outcomes. Replacement fluid, treatment frequency and the addition of IVIG may also make superficially similar studies biologically different interventions.[4][5]
- No demonstrated extension of human lifespan.
- No demonstrated reduction in major age-related clinical events.
- No validated biomarker threshold that proves patient benefit.
- No consensus longevity protocol or long-term risk-benefit estimate.
What this means for you
If you ask about plasma exchange for longevity, expect it described as emerging research, not an established therapy, since a shift in a biomarker is not the same as a health outcome. If your physician considers it clinically, the reasoning, your baseline risks, and the follow-up measures are individualized to you, and the honest possibility that it produces no meaningful benefit stays a real conclusion.[4][5]
Source register
Every material source used in this review, with the study design and the limitation that matters when interpreting it.
- [1]Mehdipour M, et al. Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin.
Aging · 2020 · Preclinical mouse study with exploratory human samples
PMID 32474458 · DOI 10.18632/aging.103418
- WHAT IT ADDS
- Supports a plasma-dilution mechanism and reports selected tissue changes in old mice.
- LIMITATION
- Predominantly preclinical and not a human longevity-outcome trial.
- [2]Mehdipour M, et al. Plasma dilution improves cognition and attenuates neuroinflammation in old mice.
GeroScience · 2021 · Preclinical mouse study
PMID 33191466 · DOI 10.1007/s11357-020-00297-8
- WHAT IT ADDS
- Reports cognitive-test and neuroinflammation changes after neutral blood exchange in old mice.
- LIMITATION
- Animal outcomes cannot establish clinical benefit in humans.
- [3]Kiprov DD, et al. Old plasma dilution reduces human biological age: a clinical study.
GeroScience · 2022 · Exploratory human biomarker study
PMID 35999337 · DOI 10.1007/s11357-022-00645-w
- WHAT IT ADDS
- Reports movement in a proposed proteomic biological-age measure.
- LIMITATION
- The biological-age measure is a surrogate and the study does not establish clinical or survival benefit.
- [4]Kiprov DD, et al. Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange.
Aging Cell · 2025 · Small randomized placebo-controlled biomarker trial
PMID 40424097 · DOI 10.1111/acel.70103
- WHAT IT ADDS
- Reports favorable changes in several molecular aging clocks in 42 participants.
- LIMITATION
- Small, surrogate-outcome study with multiple regimens and disclosed commercial involvement.
- [5]Borsky P, et al. Human clinical trial of plasmapheresis effects on biomarkers of aging.
Scientific Reports · 2025 · Stratified randomized cross-over biomarker trial
PMID 40592961 · DOI 10.1038/s41598-025-05396-0
- WHAT IT ADDS
- Found no significant epigenetic rejuvenation and unfavorable movement in several clocks.
- LIMITATION
- Tested plasmapheresis in healthy donors and does not settle other protocols or patient populations.
Research changes the question.
A physician owns the answer.
This review is educational and remains marked for clinical review. It does not determine whether any therapy is appropriate for an individual patient.